医药市场最近的话题，GLP-1减肥药可能算得上最热门的之一了，颇有一些“平生不擦减肥边，便称重磅也枉然”的架势，毕竟这是一个理论价值可能超过1000亿美元的话题。
Time：
2023-05-10 11:11
Author：
杨翼
优先审评 (Priority review) 是FDA的一项计划，目的是为了加快那些“优等生”药物的审评过程。
Time：
2023-05-10 14:45
Author：
杨翼
Time：
2023-05-10 14:50
Author：
xieyijun
长坡厚雪的赛道，也吸引了资本市场进场。而作为减肥市场上的竞争者诺和诺德与礼来，市值都超过3000亿美元。于是，减肥领域，两者开始刀枪相接，一场比降糖胰岛素更激烈的GLP-1减重战争正在展开。
Time：
2023-05-10 14:59
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务